Humanigen CEO to Present at 8th Annual LD Micro Invitational
May 30, 2018
BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announced that Cameron Durrant, M.D., chairman and CEO, will present a company overview at the 8th Annual LD Micro Invitational on Monday, June 4, 2018, at 4 p.m. PDT (7 p.m. EDT).
Dr. Durrant will discuss Humanigen’s focus to enhance T-cell therapies in oncology with its proprietary Humaneered® monoclonal antibodies, including lead asset lenzilumab as a potential prophylactic therapy to optimize treatment and minimize or prevent neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy. Lenzilumab is a first-inclass recombinant monoclonal antibody that targets and is an antagonist of soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), an upstream druggable target for inflammatory cascade side effects caused by CAR-T treatments.
A live webcast of the presentation will be available at
For more information on the conference, please visit https://www.ldmicro.com/events.
Humanigen, Inc. is a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments. Derived from the company’s Humaneered® platform, lenzilumab, ifabotuzumab and HGEN005 are monoclonal antibodies with first-inclass mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential medicine to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Eph receptor A3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a backbone for a novel CAR-T construct and bispecific antibody platform. HGEN005, which targets human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1), has potential as a treatment for eosinophilic diseases, such as a novel CAR-T construct for eosinophilic leukemia. For more information, visit www.humanigen.com.
Source: Humanigen, Inc.
Released May 30, 2018